Company Focus
Novo Nordisk
Latest Novo Nordisk News
Pharmaceutical
The US FDA's national priority voucher pilot has now run for more than a year. Announced in June 2025 as a way to cut drug review times to one or two months, it has produced 22 awards, nine approvals, one rejection, one sponsor asking to be removed, and a public hearing at which speakers asked whether the agency has the authority to run it at all. 14 August 2026
Related News
Insights
Company Spotlight
Latest News & Features of interest to Novo Nordisk
Biotechnology
US biopharma companies Fulcrum Therapeutics and Slate Medicines have agreed to combine in an all-stock merger, with the resulting entity operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker "SLTE," the companies announced Monday. 17 August 2026
Biotechnology
Danish clinical-stage techbio Evaxion, which is developing novel vaccines with its pioneering AI-Immunology platform, is expanding its pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma. The company’s shares moved up 4.8% to $3.50 in pre-market activity on the news. 17 August 2026
Biotechnology
US biotech Biogen and its Chinese partner TJ Biopharma announced that felzartamab for injection - branded Jingfei in China - has been approved by China's National Medical Products Administration (NMPA) for use with lenalidomide and dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy. 17 August 2026
Pharmaceutical
US pharma major Bristol Myers Squibb was hit with adverse developments on two separate legal fronts this month, both stemming from its 2019 acquisition of Celgene and its cardiovascular franchise. 17 August 2026
Biosimilars
Swiss affordable medicines company Sandoz today announced a major development, manufacturing and commercialization collaboration agreement with Shanghai Henlius Biotech, marking another significant step to broaden patient access to high-quality biosimilar medicines worldwide. 17 August 2026
Biotechnology
US clinical-stage biotech Neumora Therapeutics on Friday announced that Joshua Pinto has been appointed as chief executive (CEO) and a member of the board of directors. 17 August 2026
Pharmaceutical
Deal-making news last week including Spanish dermatology specialist Almirall entering into a research collaboration with China’s CrystalO Biopharma. Sentynl entered a deal to license lung disease candidate alvelestat from Mereo BioPharma, which could earn the latter nearly half a billion dollars. Also, PTC Therapeutics is acquiring Fabry disease candidate ST-920 from Sangamo competitive bankruptcy auction. On the M&A front, Jazz Pharmaceuticals announced an $820 million upfront bid to acquire Actio Biosciences and its investigational epilepsy treatment ABS-1230. 16 August 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 14 August 2026
Pharmaceutical
The US FDA's national priority voucher pilot has now run for more than a year. Announced in June 2025 as a way to cut drug review times to one or two months, it has produced 22 awards, nine approvals, one rejection, one sponsor asking to be removed, and a public hearing at which speakers asked whether the agency has the authority to run it at all. 14 August 2026
Biotechnology
USA-based CNS specialist MapLight Therapeutics announced it has secured approximately $150 million in gross proceeds through a private placement financing (PIPE). 13 August 2026
Latest In Brief for Novo Nordisk
Biotechnology
US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy privately held blood disorder drug developer Star Therapeutics amid a wave of acquisitions by midsized drugmakers looking to supplement their pipelines, according to a Financial Times report. 8 June 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze